SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant selling pressure as investors scrutinize its debt-heavy financing model and the sustainability of its Bitcoin-backed strategy. The community remains deeply polarized, with bulls viewing the pullback as a generational buying opportunity while vocal critics warn of potential insolvency and dilution risks amid the broader crypto market downturn.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a major focal point for retail investors, fueled by a narrative of potential short squeezes and long-term value plays supported by dividends and recent leadership changes. The community is actively debating the stock's susceptibility to institutional manipulation versus its intrinsic value as an international expansion story, driving heavy engagement and high daily trading volume.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys (NASDAQ: ALOY) is trending as investors react to its landmark partnership with the U.S. Army to build critical rare earth processing facilities on military bases, fueling community sentiment that the company is a core play in the push for domestic supply chain independence. Discussion is heavily focused on the stock's recent inclusion in the Russell 3000 index and its position as a strategic supplier for defense, with many participants debating the long-term potential of its mine-to-magnet infrastructure compared to competitors in the rare earths sector.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing intense downward pressure as investors remain deeply skeptical of the company's aggressive, multi-billion dollar capital expenditure into AI infrastructure with no immediate return on investment. The community is actively debating whether the stock represents a deep-value buying opportunity or is heading for further downside as it significantly lags behind other technology peers in the current market rotation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to renewed acquisition speculation and a strategic pipeline expansion following the initiation of human trials for VK3019. The community is actively debating the likelihood of a near-term buyout or partnership, fueled by broader biotech sector strength and anticipation for upcoming maintenance study data.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as a major point of contention between retail investors, who are bullish on its AI-powered features and enterprise growth, and short sellers, who have pushed the stock to record lows. The stock is seeing high volatility and heavy short interest, with the community actively debating whether the recent price decline represents a permanent collapse or a temporary washout preceding a sharp reversal.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure as investors rotate into higher-performing AI infrastructure names, leading to active community debate over whether the stock is a long-term opportunity or stuck in a stagnant phase. While some traders are focused on technical support levels and potential delivery catalysts, others are increasingly vocal about their frustration with the stock's recent underperformance and the company's valuation metrics compared to the broader tech sector.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is experiencing intense volatility and heavy trading volume as investors aggressively unwind overcrowded AI semiconductor positions, forcing a sharp correction in the KOSPI index. The community is actively debating whether this represents a temporary consolidation in a structural AI memory supercycle or a signal of a deeper, bubble-bursting market pivot.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors interpret a recent regulatory filing concerning executive change-of-control agreements as strategic preparation for a potential acquisition. This bullish sentiment is further amplified by community discussions regarding a looming clinical catalyst and significant short-covering pressure in a stock currently experiencing high borrow fees.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently the focus of intense investor debate as the stock faces relentless selling pressure, trading near 52-week lows despite community excitement over its ambitious AI-driven product roadmap, including humanoid robots and advanced autonomous driving tech. While some investors view the current valuation as a compelling entry point for a long-term turnaround play, others remain skeptical, pointing to broader macro-economic concerns, regulatory headwinds for Chinese equities, and frustration over delivery performance compared to domestic rivals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Key PointsDavid Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock...

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 8.3% - What's Next...

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside

Equity

Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - What's Next...

This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says

Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs...

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Bullish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.16	--	--	N/A
Q1 '26	-$0.14	-$0.15	-5.32%	MISSED
Q4 '25	-$0.13	-$0.15	-15.89%	MISSED
Q3 '25	-$0.13	-$0.12	5.47%	BEAT
Q2 '25	-$0.13	-$0.10	25.00%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRVSCorvus Pharmaceuticals Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CRVS News